Company Served as Sponsor and Provided Operational Leadership for Study Conducted in Partnership with TGen and Virta Health SCOTTSDALE, AZ, UNITED STATES, March 19 ...
In a randomized phase 3 trial, adding tumor debulking to first-line chemotherapy did not significantly improve overall survival or progression-free survival (PFS) and was associated with an increased ...
Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer: Results From the Randomized ...
In patients with oligometastatic prostate cancer, metastasis-directed therapy plus standard of care was associated with significant improvements in progression-free survival (PFS), radiographic PFS, ...
“Modern system-on-chips (SoCs) are becoming prone to numerous security vulnerabilities due to their ever-growing complexity and size. Therefore, a comprehensive security verification framework is ...
DUBLIN, Jan. 6, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive efficacy and safety results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera® (zanidatamab ...
The median progression-free survival was 14.5 months, and the median overall survival was 31.8 months. Peptide receptor radionuclide therapy (PRRT) retreatment may be well tolerated and confer a ...
MONDAY, Oct. 27, 2025 (HealthDay News) -- For young patients with primary multimetastatic Ewing sarcoma, pazopanib is well-tolerated and effective, according to a study published online Oct. 22 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results